What is the Motor Neurone Disease (MND) Translational Research Pipeline?
The Motor Neurone Disease (MND) Translational Research Pipeline is a grant opportunity that will support FightMND’s translational research projects in the development of innovative treatments for Motor Neurone Disease (MND).
MND, also known as Amyotrophic Lateral Sclerosis (ALS) and Lou Gehrig’s disease, refers to a group of diseases in which motor neurones progressively die. Motor neurones are nerve cells that control the movement of voluntary muscles, that is, the muscles that enable us to move, speak, swallow and breathe. With no nerves to activate them, muscles gradually weaken and waste, and paralysis ensues.
Due to its complexity and heterogeneity, MND still remains a terminal diagnosis, with no effective treatment or cure. In Australia, more than 2,000 people are living with MND and the average life expectancy after diagnosis is only 2.5 years (Economic analysis of MND in Australia, 2015). Hence, the imperative need to find a therapy that can slow, halt or reverse the disease.
It contributes to the achievement of the Department of Health’s Outcome1 Health Policy, Design and Innovation, under Program 1.1 Health Policy Research and Analysis.
The objectives of this grant opportunity are:
- to support research that identifies new targets for therapeutic intervention for MND;
- to support research and development of innovative treatments and therapies for MND; and
- improve research translation into best practice treatment and therapies for MND.
The intended outcomes of the grant are:
- to address gaps of knowledge of the disease processes that support the identification of novel targets specific to MND for the development of more effective disease modifying treatments; and
- to address a lack of basic research to understand how best to apply therapeutic advances in other neurological diseases to the development of novel approaches to treating MND, including inherited MND.
This grant will be administered by the Community Grants Hub on behalf of the Department of Health.
The Australian Government will contribute a total of up to $3 million (GST exclusive) over 1 year in (2019-20) for this grant opportunity.
To be eligible your project must:
- be aimed at the objectives and outcomes; and
- include one or more of the following research activities:
- research into disease heterogeneity,
- research into disease biomarkers,
- research into disease models,
- research into regenerative medicine,
- research into gene therapy
Costs that the grant can be used for must be:
- incurred by you within the project period;
- a direct cost of the project;
- incurred by you to undertake required project audit activities;
- direct labour cost of employees you directly employ on the core elements of the project;
- salary on-cost limited to employer superannuation, payroll tax and worker’s compensation insurance. Salary on-cost should be reasonable and be identified in the project budget submitted with the application;
- contract expenditure is the cost of any agreed project activities that you contract to others;
- staff training that directly supports the achievement of the project outcomes;
- the cost of independent audit of the project expenditure, if applicable; and
- other eligible expenditure as approved by the Program Delegate.
To be eligible to apply you must be the listed organisation:
- Cure for MND Foundation Inc (FightMND) | ABN No. 627 403 507 04
FightMND is invited to apply for this grant opportunity as they have been assessed to have:
- demonstrated capability to deliver the project activities;
- existing infrastructure and relationships to support the project activities; and
- knowledge of and capability to deliver to the project objectives and outcomes.
Applications close 12 February 2020.